Obesity-focused biotech BioAge Labs said on Wednesday it was seeking a valuation of as much as $587 million in its initial ...
The results jibe with earlier research showing that childhood obesity rates are steadily rising, even though food insecurity ...
Why Corbus Pharmaceuticals sees Novo Nordisk’s controversial approach to obesity drugs as a ticket to a blockbuster.
The European Medicines Agency backed the use of Novo Nordisk's Wegovy in patients with an obesity-related heart condition, ...
"When you have two-thirds plus of the active duty military force that's obese ... you know you've got a huge problem," ...
The company is offering 7.5 million shares for $17 to $19 apiece, according to a filing Wednesday ...
Evidence shows that blockbuster weight-loss medications can reduce obesity even in children aged 6–11, but their long-term ...
Research in people with obesity or overweight has shown that long-term exercisers have belly fat with healthier properties ...
The release of early-stage data on three oral weight loss drug candidates hints at which companies have the strongest hand, ...
BioAge Labs Inc., a clinical-stage biotechnology company developing therapies for obesity and metabolic disease, is seeking ...
12hOpinion
It’s a brain disease,” a prominent obesity doctor explained on a “60 Minutes” episode about the drugs. “Obesity is disease” ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback